Atherosclerosis Drugs Market: Nanotechnology to Upgrade Quality of Drugs
Competency of nano polymers in imaging further broadens the scope of nanotechnology in the diagnosis of cardiovascular disorders, which makes it the present and the future technology of atherosclerosis drugs.
Nanotechnology is adding a new paradigm in the development of atherosclerosis drugs, owing to its selective drug delivery system that only targets damaged tissues. One such nano polymer, E-selectin-targeting polymer, is used for imaging and drug delivery applications to improve the function of heart muscles.
Though technological advancements and demand for drugs are growing at a notable rate, a large number of individuals remain undiagnosed. Low diagnostic rates could hamper the growth potential of the atherosclerosis drugs market during the forecast period (2020-2027).
Know More Details About the Report
Retail Pharmacies Gaining Prominence in Atherosclerosis Drugs Market
Hospital pharmacies boast of well-stocked inventory with a wide range of prescribed and OTC medications, which makes it convenient for individuals to makes purchases immediately after diagnosis. Numerous government-held hospital pharmacies offer medications at low rates, which further becomes a viable sales opportunity.
Hospital pharmacies are projected to account for around 46% share in the atherosclerosis drugs market by 2027. However, they could lose market share to retail pharmacies, to some extent, on the back of a large chain of retail pharmacies at key locations, which makes it easy for individuals to refill their drug supplies.
Besides this, in recent times, retail pharmacists are also playing a consultative role, which is likely to influence reliance on retail pharmacies. On account of growing popularity, retail pharmacies are set to register a value equal to US$ 24 Bn by 2027.
Avail customized purchase options for your needs
Growing Popularity of Generic Drugs – A Concern for North America, an Opportunity for Asia Pacific
Powerful forces at play attributing a high share to the North American atherosclerosis drugs market majorly include large public funding. The American Heart Association actively supports the research & development endeavours of market players, intended towards improving the cardiovascular health of the U.S. population.
Besides this, initiatives taken by the government to upgrade healthcare infrastructure and increase awareness regarding the treatment of numerous disorders are likely to augment diagnostic and drug adoption rates. On the back of numerous favourable drivers, the North America atherosclerosis drugs market is projected to account for 34% market share by 2027.
Though North America holds a leading position in the global atherosclerosis drugs market, increasing sales of generic drugs are impeding the revenue potential of leading players operating in this region. However, the Asia Pacific atherosclerosis drugs market is thriving on the back of growing sales of generic drugs, as a large number of prominent and emerging players are working towards their development.
In addition, Asia Pacific is a price-sensitive region, wherein, affordability of individuals plays a pivotal role in their purchase decisions. Growing preference for generic drugs over branded ones, in parallel with rising awareness regarding atherosclerosis disorders, would create a conducive environment for market growth during the forecast period.
An Adaptive Approach to Modern-day Research Needs
Atherosclerosis Drugs Market – Assessment of Key Segments
Authors of this comprehensive study have classified the atherosclerosis drugs market into key segments for an in-depth study of the market. Categorisation of the atherosclerosis drugs market is based on drug class, distribution channel, and region. This detailed study also offers information about the incremental opportunity present in the atherosclerosis drugs market during the forecast period. Key segments considered while studying the atherosclerosis drugs market include:
Atherosclerosis Drugs Market – Scope of the Report
The study on the atherosclerosis drugs market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that are driving the growth of the market.
This exclusive study provides incisive insights regarding recent developments in the atherosclerosis drugs market, by analysing the historical data for the period of 2017-2019, and the duration of 2020-2027 that is considered as the forecast period.
Evaluation of the atherosclerosis drugs market’s revenue has been carried out in terms of value (US$ Mn). This research provides information into the key trends that are potential enough to influence the growth of the atherosclerosis drugs market.
Besides this, the study also includes several macroeconomic and microeconomic growth indicators complementing the growth of the atherosclerosis drugs market during the forecast period. This detailed study provides information into key dynamics, and their influence on the atherosclerosis drugs market during the forecast period.
The report also provides information about the key challenges and threats that could deter the growth potential of players in the atherosclerosis drugs market. The study unveils profitable opportunities for manufacturers, which they can adopt to strengthen their position in the global atherosclerosis drugs market. With a view of aiding stakeholders in the atherosclerosis drugs market, the study comprises a detailed section on the competition analysis.
This exclusive study offers a dashboard view of the atherosclerosis drugs market, with detailed information about market players, based on overall revenue, key developments, and their market presence. Additionally, key strategies of players in the atherosclerosis drugs market have also been included in this comprehensive study.
Revenue of the atherosclerosis drugs market has been evaluated in terms of US$ Mn for the period of 2020 to 2027. In addition to this, compound annual growth rate has been calculated for all key segments for the forecast period of 2020-2027, considering 2019 as the base year.
Authors of this exclusive study on the atherosclerosis drugs market have analysed key players, based on their financials, products, and strategies, in order to provide key detailed information into the competitive landscape. Key players operating in the atherosclerosis drugs market include Pfizer Inc., GlaxoSmithKline PLC, Amgen Inc., Sanofi, Mylan N.V., F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Bayer AG, Merck & Co., Inc., and Novartis AG.
This exclusive study is produced to offer a detailed perspective of the atherosclerosis drugs market to stakeholders, who include companies and intermediaries engaged in the development, manufacturing, and commercialisation of drugs. The report is also aimed at offering crucial information about the atherosclerosis drugs market to new players.
Atherosclerosis Drugs Market – Research Methodology
The primary objective of this exclusive study on the atherosclerosis drugs market is to offer precise estimates and forecasts of the market in terms of value (US$ Mn) for the period of 2020-2027.
The secondary objective includes analysis of key market segments exhibiting significant growth rates, leading strategies adopted by players in the atherosclerosis drugs market, and the adoption rate of atherosclerosis drugs in key regions across the world.
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.